This new weight loss drug, expected to be available before 2030, offers a promising option for those seeking effective weight management solutions
By stimulating these receptors, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying
typically, it takes about 17 weeks to reach final maintenance
The drug also improved several cardiovascular risk markers, including waist size, cholesterol levels, triglycerides, blood pressure and inflammation levels
GLP-1 medications alter the environment in which gut bacteria operate, and early research suggests this can shift microbial populations in ways that may contribute to digestive symptoms